TY - JOUR
T1 - Effects of Echothiophate on Enzymatic Hydrolysis of Dipivefrin
AU - Anderson, Janet A.
AU - Richman, Joseph B.
AU - Mindel, Joel S.
PY - 1984/6
Y1 - 1984/6
N2 - Dipivefrin is an antiglaucoma prodrug that is hydrolyzed to the active drug, epinephrine, by esterases in the cornea. Since cholinergic antiglaucoma agents are frequently used in combination with adrenergic agents, it was of interest to determine the effects of a commonly used irreversible cholinesterase inhibitor, echothiophate (Phospholine) iodide, on the dipivefrin esterases. In vitro studies showed that echothiophate is a competitive, reversible inhibitor of the soluble corneal dipivefrin esterases. In vivo studies substantiated the reversible nature of echothiophate inhibition, since no inhibition of dipivefrin hydrolysis could be detected 1% hours after echothiophate treatment and as early as 15 minutes after dipivefrin application.
AB - Dipivefrin is an antiglaucoma prodrug that is hydrolyzed to the active drug, epinephrine, by esterases in the cornea. Since cholinergic antiglaucoma agents are frequently used in combination with adrenergic agents, it was of interest to determine the effects of a commonly used irreversible cholinesterase inhibitor, echothiophate (Phospholine) iodide, on the dipivefrin esterases. In vitro studies showed that echothiophate is a competitive, reversible inhibitor of the soluble corneal dipivefrin esterases. In vivo studies substantiated the reversible nature of echothiophate inhibition, since no inhibition of dipivefrin hydrolysis could be detected 1% hours after echothiophate treatment and as early as 15 minutes after dipivefrin application.
UR - https://www.scopus.com/pages/publications/0021238028
U2 - 10.1001/archopht.1984.01040030733032
DO - 10.1001/archopht.1984.01040030733032
M3 - Article
C2 - 6732575
AN - SCOPUS:0021238028
SN - 0003-9950
VL - 102
SP - 913
EP - 916
JO - Archives of Ophthalmology
JF - Archives of Ophthalmology
IS - 6
ER -